Continue Phototherapy with Close Monitoring
For this 6-day-old infant whose TSB decreased from 16.5 to 15.6 mg/dL, you should continue intensive phototherapy until the bilirubin drops 2-4 mg/dL below the hour-specific phototherapy threshold for this infant's age and risk factors 1.
Rationale for Continuing Treatment
The 2024 AAP guidelines are explicit: phototherapy discontinuation is an option when TSB has declined by 2-4 mg/dL below the hour-specific threshold at which phototherapy was initiated 1. Your infant has only dropped 0.9 mg/dL—insufficient to meet discontinuation criteria.
Key Decision Points:
At 144 hours of age (6 days), you need to determine this infant's specific phototherapy threshold based on:
- Gestational age (term vs preterm)
- Presence of neurotoxicity risk factors
- The hour-specific nomogram threshold
The decline must be 2-4 mg/dL below the threshold, not just any decline. If phototherapy was initiated at 16.5 mg/dL, this suggests the threshold was likely around 14-15 mg/dL for this infant's age and risk category. The current level of 15.6 mg/dL has not yet achieved adequate separation from the threshold 1.
Monitoring Strategy
Measure TSB to verify phototherapy efficacy, with timing guided by the initial TSB trajectory 1. Given the modest decline over the treatment period, recheck TSB in 12-24 hours to ensure continued downward trend.
Critical Red Flags to Assess:
Rate of rise before treatment: If the initial rise was ≥0.2 mg/dL per hour (after 24 hours of age), this suggests hemolysis and warrants investigation for underlying causes 1
Inadequate response: If TSB rises despite intensive phototherapy, rises suddenly, or rises after initial decline, immediately check G6PD enzyme activity and consider escalation of care 1
Post-Discontinuation Planning
When you eventually discontinue phototherapy (after achieving 2-4 mg/dL drop below threshold):
High-risk infants requiring closer follow-up (measure TSB 8-12 hours after stopping, then next day) 1:
- Phototherapy started <48 hours of age
- Gestational age <38 weeks
- Positive direct antiglobulin test (DAT)
- Suspected hemolytic disease
Standard-risk infants: Follow-up TSB within 1-2 days after discontinuation 1
Evidence on Rebound
Research shows rebound hyperbilirubinemia occurs more frequently in infants treated during birth hospitalization (8.2%) versus those readmitted for phototherapy (0.7%) 2. The mean rebound is typically 1.3 mg/dL, occurring around 12-14 hours after discontinuation 2, 3. However, discontinuing at higher bilirubin levels (as you're considering) without adequate decline below threshold increases rebound risk.
Common Pitfalls to Avoid
Don't use transcutaneous bilirubin (TcB) for treatment decisions—TSB is the definitive diagnostic test 1. TcB can only be used ≥24 hours after phototherapy stops 1.
Don't discontinue based solely on absolute TSB value—the decision requires knowing the hour-specific threshold and achieving 2-4 mg/dL separation below it 1.
Don't assume all declines are adequate—individualize based on the cause of hyperbilirubinemia, initial TSB level, and rebound risk 1.
The evidence is clear that premature discontinuation risks rebound requiring retreatment, which is more common when phototherapy stops during birth hospitalization 2. Continue treatment until appropriate separation from threshold is achieved to prevent kernicterus—the ultimate outcome we're preventing 1.